Q-omics provides the consensus-scored DNM1P38 profile across patient tissues and cancer cell-line models. DNM1P38 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DNM1P38 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, DNM1P38 RNA expression shows 5,838 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, and STAD as cancer lineages where DNM1P38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNM1P38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNM1P38 survival associations across molecular data types. DNM1P38 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNM1P38 RNA expression–survival associations across cancer types. High DNM1P38 expression shows unfavorable associations in KIRP, UCEC, THCA, LIHC and PRAD, but favorable associations in COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for DNM1P38 RNA expression.
This table summarizes DNM1P38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DNM1P38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNM1P38 shows higher tumor expression in STAD and KIRC. The STAD box plot shows higher DNM1P38 RNA expression in tumor versus normal tissue (log2 FC = +0.083, t-test p = .007).
This table shows molecular features associated with DNM1P38 in patient tissues and cancer cell lines. In patient samples, DNM1P38 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
